Concepedia

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial

Jelena P. Seferović, Brian Claggett, Sara B. Seidelmann, Ellen W. Seely, Milton Packer, Michael R. Zile, Jean L. Rouleau, Karl Swedberg, Martin Lefkowitz, Victor Shi,

The Lancet Diabetes & Endocrinology · 2017 · 355 citations · 33 references

DOI

Concepts

References

33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

John J.V. McMurray, Milton Packer, Akshay S. Desai et al. · New England Journal of Medicine · 2014 · 6.8K citations · Full text

, , +11

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text

, , +14

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text

, , +15